The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan

Huang, Yen-HsiangYen-HsiangHuangHsu, Kuo-HsuanKuo-HsuanHsuTseng, Jeng-SenJeng-SenTsengYang, Tsung-YingTsung-YingYangChen, Kun-ChiehKun-ChiehChenKANG-YI SUSUNG-LIANG YUChen, Jeremy J WJeremy J WChenChang, Gee-ChenGee-ChenChang2022-05-122022-05-122022-04-231776-2596https://scholars.lib.ntu.edu.tw/handle/123456789/610530Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors are the standard first-line treatment for patients with advanced and recurrent EGFR-positive non-small cell lung cancer.enOPEN-LABEL; GEFITINIB; ADENOCARCINOMA; MUTATIONS[SDGs]SDG3The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwanjournal article10.1007/s11523-022-00878-x354604742-s2.0-85128768264WOS:000785956400002https://api.elsevier.com/content/abstract/scopus_id/85128768264